MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, JANX had -$378,271K decrease in cash & cash equivalents over the period. -$83,278K in free cash flow.

Cash Flow Overview

Change in Cash
-$378,271K
Free Cash flow
-$83,278K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of short-term investm...
    • Accrued expenses
    • Proceeds from exercise of common...
    • Others
Negative Cash Flow Breakdown
    • Purchases of short-term investme...
    • Net loss
    • Accretion of discounts on invest...
    • Others

Cash Flow
2025-12-31
Net loss
-113,625
Depreciation
2,029
Stock-based compensation
40,221
Accretion of discounts on investments, net
17,574
Prepaid expenses and other current assets
827
Other long-term assets
-276
Accounts payable
977
Accrued expenses
6,290
Deferred revenue
0
Operating lease right-of-use assets and liabilities, net
2
Net cash used in operating activities
-82,235
Purchases of property and equipment
1,043
Purchases of short-term investments
705,222
Maturities of short-term investments
405,284
Net cash used in investing activities
-300,981
Proceeds from exercise of common stock options and employee stock purchase plan
5,292
Proceeds from the issuance of common stock and pre-funded common stock warrants, net of issuance costs
-347
Net cash provided by financing activities
4,945
Net increase (decrease) in cash, cash equivalents and restricted cash
-378,271
Cash, cash equivalents and restricted cash - beginning of year
431,421
Cash, cash equivalents and restricted cash - end of period
53,150
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from exercise ofcommon stock options...$5,292K Net cash provided byfinancing activities$4,945K Canceled cashflow$347K Net increase(decrease) in cash, cash...-$378,271K Canceled cashflow$4,945K Maturities of short-terminvestments$405,284K Stock-based compensation$40,221K Accrued expenses$6,290K Depreciation$2,029K Accounts payable$977K Other long-termassets-$276K Proceeds from theissuance of common stock...-$347K Net cash used ininvesting activities-$300,981K Net cash used inoperating activities-$82,235K Canceled cashflow$405,284K Canceled cashflow$49,793K Purchases of short-terminvestments$705,222K Net loss-$113,625K Purchases of property andequipment$1,043K Accretion of discounts oninvestments, net$17,574K Prepaid expenses andother current assets$827K Operating leaseright-of-use assets and...$2K

Janux Therapeutics, Inc. (JANX)

Janux Therapeutics, Inc. (JANX)